EICHORPublic-registry site landscape for NCT07683000, “Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens”, a HIV-1-infection study sponsored by Gilead Sciences. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07683000 (registry record) |
| Study title | Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens |
| Official title | A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to a Regimen of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir Twice-Yearly in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens |
| Sponsor | Gilead Sciences |
| Condition(s) | HIV-1-infection |
| Phase | PHASE3 |
| Listed sites | 0 |
Patient-friendly overview of this study: eichor.com/study/NCT07683000.
Eichor generates a preliminary site-risk snapshot for NCT07683000 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
